Molecular Approaches in Single Ventricle Management.

Area of Science:

• Cardiovascular Medicine
• Pediatric Cardiology
• Molecular Biology

Background:

• Medical and surgical advances have improved early outcomes for single ventricle congenital heart disease (SV-CHD).
• Long-term outcomes for SV-CHD patients remain suboptimal, with limited therapeutic options for ventricular or Fontan failure.
• Understanding the molecular basis of SV-CHD is crucial for developing new treatments.

Purpose of the Study:

• To review the current state of single ventricle congenital heart disease management.
• To highlight the role of molecular biology in understanding SV-CHD.
• To discuss emerging cell-based and biological therapies for SV-CHD.

Main Methods:

• Review of recent advancements in medical and surgical management of SV-CHD.
• Exploration of molecular biologic techniques applied to SV-CHD.
• Discussion of current and future cell-based and biological therapies.

Main Results:

• Early outcomes in SV-CHD have improved, but long-term results are still suboptimal.
• Molecular biology is revealing disease mechanisms, aiding in diagnosis and prognostication.
• Cell-based therapies are entering clinical practice, with more novel biological therapies anticipated.

Conclusions:

• Molecular medicine holds significant promise for the next generation of SV-CHD therapies.
• Continued research into molecular mechanisms and biological therapies is essential.
• Future management of SV-CHD will likely involve innovative, personalized therapeutic approaches.